Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-26-010656
Filing Date
2026-03-23
Accepted
2026-03-23 08:44:09
Documents
12
Period of Report
2026-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20068452_8ka.htm   iXBRL 8-K/A 31110
2 EXHIBIT 10.1 ef20068452_ex10-1.htm EX-10.1 280998
  Complete submission text file 0001140361-26-010656.txt   488588

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20260303.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20260303_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20260303_pre.xml EX-101.PRE 16042
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20068452_8ka_htm.xml XML 4210
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K/A | Act: 34 | File No.: 001-40782 | Film No.: 26780015
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)